ATYR Q4 2022 Earnings — aTyr Pharma, Inc. Revenue & Financial Results | Market Cap Arena

ATYRaTyr Pharma, Inc.

$93M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M

Gross Profit

$10M93.3% margin

Operating Income

-$8M-76.5% margin

Net Income

-$8M-72.4% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$605,000

Balance Sheet

Total Assets

$96M

Total Liabilities

$25M

Stockholders' Equity

$71M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$0	—
Gross Profit	$10M	$0	—
Operating Income	-$8M	-$9M	+8.0%
Net Income	-$8M	-$9M	+12.1%